These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 16105567

  • 21. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW, Neumiller JJ, Setter SM.
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [Abstract] [Full Text] [Related]

  • 22. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 23. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC, Leclercq R, Debbia EA, Cantón R, Oppenheim BA, Dowzicky MJ.
    Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
    [Abstract] [Full Text] [Related]

  • 24. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA, Koch KM, Dowzicky MJ.
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [Abstract] [Full Text] [Related]

  • 25. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2017 Jul 12; 16(1):50. PubMed ID: 28701170
    [Abstract] [Full Text] [Related]

  • 26. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ.
    Expert Rev Anti Infect Ther; 2006 Feb 12; 4(1):9-25. PubMed ID: 16441206
    [Abstract] [Full Text] [Related]

  • 27. Tigecycline.
    Pankey GA.
    J Antimicrob Chemother; 2005 Sep 12; 56(3):470-80. PubMed ID: 16040625
    [Abstract] [Full Text] [Related]

  • 28. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan 12; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 29. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Study Group.
    Diagn Microbiol Infect Dis; 2010 Feb 12; 66(2):187-94. PubMed ID: 19836184
    [Abstract] [Full Text] [Related]

  • 30. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE, Rybak MJ.
    Pharmacotherapy; 2006 Aug 12; 26(8):1099-110. PubMed ID: 16863487
    [Abstract] [Full Text] [Related]

  • 31. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.
    Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC.
    Int J Antimicrob Agents; 2012 Jun 12; 39(6):490-5. PubMed ID: 22534507
    [Abstract] [Full Text] [Related]

  • 32. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May 12; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 33. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, Mulvey MR, Hoban DJ, Canadian Antimicrobial Resistance Alliance.
    Diagn Microbiol Infect Dis; 2008 Sep 12; 62(1):67-80. PubMed ID: 18513913
    [Abstract] [Full Text] [Related]

  • 34. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN, Kirby JT, Rhomberg PR.
    Diagn Microbiol Infect Dis; 2008 Jun 12; 61(2):203-13. PubMed ID: 18329835
    [Abstract] [Full Text] [Related]

  • 35. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
    Zhang YY, Zhou L, Zhu DM, Wu PC, Hu FP, Wu WH, Wang F.
    Diagn Microbiol Infect Dis; 2004 Dec 12; 50(4):267-81. PubMed ID: 15582300
    [Abstract] [Full Text] [Related]

  • 36. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA, Weaver-Sands DT, Petersen PJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [Abstract] [Full Text] [Related]

  • 37. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.
    Draghi DC, Tench S, Dowzicky MJ, Sahm DF.
    Chemotherapy; 2008 Sep 01; 54(2):91-100. PubMed ID: 18303257
    [Abstract] [Full Text] [Related]

  • 38. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
    Vouillamoz J, Moreillon P, Giddey M, Entenza JM.
    J Antimicrob Chemother; 2008 Feb 01; 61(2):371-4. PubMed ID: 18033780
    [Abstract] [Full Text] [Related]

  • 39. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
    Somily AM, Al-Khattaf AS, Kambal AM.
    Saudi Med J; 2010 Jan 01; 31(1):18-24. PubMed ID: 20062893
    [Abstract] [Full Text] [Related]

  • 40. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec 01; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.